
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio is viewed favorably because GRI-0621 has already shown clinically meaningful IPF signals, including placebo-adjusted FVC gains of 99 ml as monotherapy and 139 ml with standard of care, plus a clean 12-week safety profile. The deeper biomarker package from 35 Phase 2a patients strengthens confidence that the drug is not merely symptomatic, but is acting through immune rebalancing, reduced lung injury, fibrosis resolution, and tissue repair across multiple assays. With IPF affecting about 140,000 U.S. patients, no debt, and $11 million in cash in Q2, the company has a differentiated lead asset and enough runway to pursue the next regulatory path.
Bears say
GRI Bio is exposed to substantial fundamental risk because its prospects depend on early-stage clinical assets that must still prove safety and efficacy, secure regulatory approvals, and ultimately achieve commercialization and reimbursement. The company also faces balance sheet and liquidity pressure, while macroeconomic conditions, biotech investor sentiment, and shifting consumer or government healthcare priorities can further undermine funding access and valuation. With competition intensifying and key programs such as GRI-0621 and GRI-0803 still dependent on clinical validation, the business remains highly uncertain and vulnerable to multiple execution failures.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About GRI Bio Inc (GRI) Forecast
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares